Skip Navigation
  Search Menu
Find an Expert

 

Garry R Cutting, M.D.

Photo of Dr. Garry R Cutting, M.D.

Aetna/U.S. Healthcare Professor of Medical Genetics

Professor of Pediatrics

Male

Expertise: Cystic Fibrosis, Genetics, Medical Genetics

Request an Appointment

I live in Maryland

410-955-3071
Request an appointment through MyChart!

I live outside of Maryland

410-464-6641
Request Appointment

I live outside of the United States

+1-410-502-7683
Request Appointment

Locations

Broadway Research Building

APPOINTMENT PHONE: 410-955-3071

733 N. Broadway Suite 551 Baltimore, MD 21287 map

The Johns Hopkins Hospital (Main Entrance)

APPOINTMENT PHONE: 410-955-3071

1800 Orleans St. Baltimore, MD 21287 map

Background

Dr. Garry R. Cutting is a Professor of Pediatrics and Medicine in the McKusick-Nathans Institute of Genetic Medicine of the Johns Hopkins University School of Medicine.  He is the Aetna/U.S. Healthcare Professor of Medical Genetics at Johns Hopkins.  Dr. Cutting received his undergraduate degree in biology and medical degree from the University of Connecticut.  He completed residency training in pediatrics and a fellowship in medical genetics at the Johns Hopkins University School of Medicine.  Dr. Cutting is the Medical Director of the DNA Diagnostic Laboratory of Johns Hopkins Genomics.  He directed the Medical Genetics Residency Program at Hopkins from 1995 to 2004.

Dr. Cutting is the recipient of the Paul di Sant’Agnese Distinguished Scientific Achievement Award from the Cystic Fibrosis Foundation and a MERIT award from the National Institutes of Health. He has published more than 160 peer-reviewed articles. Dr. Cutting was elected to the Society of Pediatric Research (1992), the American Society of Clinical Investigation (1995) and the Association of American Physicians (2017).   

Dr. Cutting’s primary interests lie in the interpretation of DNA variation and their effect upon human phenotypes.  Dr. Cutting’s lab focuses on the effect of common and rare variants in the CFTR gene that cause the single gene disorder cystic fibrosis (CF).  His lab operates the CFTR2 database, a resource composed of clinical and genetic data on almost 90,000 individuals with CF world-wide.  His laboratory also studies the effect of clinically approved and novel modulators upon CFTR protein bearing disease-causing variants.  Dr. Cutting’s laboratory is also leader in the identification and characterization of genetic modifiers of cystic fibrosis.  His group is currently collaborating with teams at the University of North Carolina and the University of Washington, Seattle to identify common and rare modifier variants of disease severity by whole genome sequencing of 5200 individuals with CF.  Dr. Cutting participates in the clinical translation of variant interpretation as the Medical Director of the DNA Diagnostic Laboratory at Johns Hopkins.  Finally, as Editor of the journal Human Mutation Dr. Cutting oversees the review and publication of manuscripts reporting the mechanism, distribution and phenotype consequences of variation in our genomes.

...read more

Titles

  • Aetna/U.S. Healthcare Professor of Medical Genetics
  • Director, Postdoctoral Clinical Genetics Fellowship Programs
  • Preceptor, Predoctoral Training Program in Human Genetics
  • Director, DNA Diagnostic Laboratory
  • Director, Genetic Translational Technology Core
  • Director, Medical Genetics Training Program
  • Professor of Pediatrics

Departments / Divisions

Education

Degrees

  • MD, UConn John Dempsey Hospital (1983)

Board Certifications

  • American Board of Medical Genetics and Genomics / Clinical Biochemical Genetics (1990)
  • American Board of Medical Genetics and Genomics / Clinical Genetics / MD (1990)
  • American Board of Medical Genetics and Genomics / Clinical Molecular Genetics (1990)
  • American Board of Pediatrics / Pediatrics (1987)

Research & Publications

Research Summary

Dr. Cutting’s primary interests lie in the interpretation of DNA variation and their effect upon human phenotypes.  Dr. Cutting’s lab focuses on the effect of common and rare variants in the CFTR gene that cause the single gene disorder cystic fibrosis (CF).  His lab operates the CFTR2 database, a resource composed of clinical and genetic data on almost 90,000 individuals with CF world-wide.  His laboratory also studies the effect of clinically approved and novel modulators upon CFTR protein bearing disease-causing variants.  Dr. Cutting’s laboratory is also leader in the identification and characterization of genetic modifiers of cystic fibrosis.  His group is currently collaborating with teams at the University of North Carolina and the University of Washington, Seattle to identify common and rare modifier variants of disease severity by whole genome sequencing of 5200 individuals with CF.  Dr. Cutting participates in the clinical translation of variant interpretation as the Medical Director of the DNA Diagnostic Laboratory at Johns Hopkins.  Finally, as Editor of the journal Human Mutation Dr. Cutting oversees the review and publication of manuscripts reporting the mechanism, distribution and phenotype consequences of variation in our genomes.

Lab Website: DNA Diagnostic Lab

Selected Publications

View all on Pubmed

Masica DL, Sosnay PR, Raraigh KS, Cutting GR, Karchin R. "Missense variants in CFTR nucleotide-binding domains predict quantitative phenotypes associated with cystic fibrosis disease severity." Hum Mol Genet. 2014 Dec 8. pii: ddu607. [Epub ahead of print]

Cutting GR. "Cystic fibrosis genetics: from molecular understanding to clinical application." Nat Rev Genet. 2015 Jan;16(1):45-56. doi: 10.1038/nrg3849. Epub 2014 Nov 18.

Collaco JM, Blackman SM, Raraigh KS, Morrow CB, Cutting GR, Paranjape SM. "Self-reported exercise and longitudinal outcomes in cystic fibrosis: a retrospective cohort study." BMC Pulm Med. 2014 Oct 6;14:159. doi: 10.1186/1471-2466-14-159.

Hampton TH, Green DM, Cutting GR, Morrison HG, Sogin ML, Gifford AH, Stanton BA, O'Toole GA. "The microbiome in pediatric cystic fibrosis patients: the role of shared environment suggests a window of intervention." Microbiome. 2014 Apr 28;2:14. doi: 10.1186/2049-2618-2-14. eCollection 2014.

Sharma N, Sosnay PR, Ramalho AS, Douville C, Franca A, Gottschalk LB, Park J, Lee M, Vecchio-Pagan B, Raraigh KS, Amaral MD, Karchin R, Cutting GR. "Experimental assessment of splicing variants using expression minigenes and comparison with in silico predictions." Hum Mutat. 2014 Oct;35(10):1249-59. doi: 10.1002/humu.22624. Epub 2014 Sep 10.

Zeitlin PL, Lu L, Hwang TC, Rhim J, Craig R, Cutting GR, Stetten G, Kieffer KA, Guggino WB. A Cystic Fibrosis bronchial epithelial cell line: Immortalization by Adeno-12 SV-40 infection. Am J Resp Cell and Mol Biol (1991), 4:313-319.

McColley SA, Rosenstein BJ, Cutting GR. Differences in Expression of Cystic Fibrosis in Blacks and Whites. Am J Dis Child (1991), 145:94-97.

Nunes V, Gaona MC, Mana P, Casals T, Cutting GR, Estivill X: Prenatal diagnosis of cystic fibrosis by simultaneous analysis of two different mutations. Prenatal Diagnosis (1991) 11:671-672.

Beaudet AL, Perciaccante RG, Cutting GR. Homozygous nonsense mutation causing cystic fibrosis with uniparental disomy. Am. J. Hum. Genet. (1991) 48:1213.

Cutting GR, Kasch LM, Rosenstein BJ, Zielensky J, Tsui L-C, Antonarakis SE, Kazazian H Jr. A cluster of Cystic Fibrosis mutations in the first nucleotide binding fold domain of the Cystic Fibrosis conductance regulator protein. Nature (1990), 346:366-369.

Cutting GR, Kasch LM, Rosenstein BJ, Tsui L-C, Kazazian H and Antonarakis SE. Two patients with Cystic Fibrosis, nonsense mutations in each Cystic Fibrosis gene, and mild pulmonary disease. New Engl J Med (1990), 323:1685-1689.

Cutting GR, Kasch LM. Worldwide survey of the deltaF508 mutation-report from the Cystic Fibrosis Genetic Analysis Consortium. Am J Hum Genet (1990), 47:354-359.

Cutting GR, McGinniss MJ, Kasch LM, Tsipouras P, Antonarakis SE. Physical mapping by PFGE localizes the COL3A1 and COL5A2 genes to a 35kb region on chromosome 2. Genomics (1990), 8:407-410.

Cutting GR, Antonarakis SE, Beutow KH, Kasch LM, Rosenstein BJ, Kazazian H Jr. Analysis of DNA polymorphism haplotypes linked to the Cystic Fibrosis locus in North American Black and Caucasian families support the existence of multiple mutations of the Cystic Fibrosis gene. Am J Hum Genet (1989), 44:307-318.

Jabs EW, Goble CA, Cutting GR. The macromolecular organization of human centromeric region reveals high frequency, polymorphic macro-DNA repeats. Proc Natl Acad Sci (USA) (1989), 86:202-206.

Cutting GR, Kazazian H Jr, Antonarakis SE, Killen PD, Yamada Y and Francomano CA. Macrorestriction mapping of human collagen genes COL4A1 and COL4A2 on chromosome 13q34. Genomics (1988), 3:256-263.

Cutting GR, Antonarakis SE, Youssoufian H and Kazazian H Jr. The accuracy and limitations of Pulsed Field Gel Electrophoresis in sizing partial deletions of the factor VIII gene. Molecular Biology and Medicine (1988), 5:173-184.

Academic Affiliations & Courses

Courses and Syllabi

  • Introduction to Pathobiology
  • Analytical Methods in Clinical Medicine
  • Jackson Lab Course
  • Human Genetics Lecture Series
  • Advanced Topics in Human Genetics
  • Molecular Mechanisms
  • Cellular and Molecular Medicine
  • Molecules and Cells Course

Activities & Honors

Honors

  • Paul di Sant’Agnese Distinguished Scientific Achievement Award, Cystic Fibrosis Foundation
  • MERIT Award, National Institutes of Health
  • Merck Clinician Scientist Award
  • Linda Ives Award, Basic Science Research in Pediatrics
  • Electee, Association of American Physicians, 2017

Memberships

  • Faculty Advancement Committee
  • Human Genetics Committee
  • U.S. Cystic Fibrosis Foundation

Professional Activities

  • Director, CFTR2 project
  • Director, Clinical Genetics Laboratory Training Programs
  • Preceptor, Predoctoral Training Program in Human Genetics
  • Director, DNA Diagnostic Laboratory
  • Director, Genetic Translational Technology Core

Videos & Media

Lectures and Presentations

  • Identification of Sequences Conferring Unique Properties to GABAC Receptors Formed of ? Subunits
    Symposium Presentation, Ft. Lauderdale (01/01/1900)
    Association for Research in Vision & Ophthalmology Annual Meeting
  • Genetic Aspects of Chronic Sinusitis
    Presentation, Scottsdale (01/01/1900)
    American Academy of Allergy Asthma & Immunology
  • Mutation Analysis in Cystic Fibrosis
    Symposium Presentation, Jerusalem (01/01/1900)
    XIIth International Cystic Fibrosis Congress
  • Implications of the Multiple Functions of CFTR and Therapy for CF and Gene Therapy for Cystic Fibrosis
    Symposium Presentations, Rio de Janeiro (01/01/1900)
    9th International Congress of Human Genetics
  • Consequences of CF Mutation Upon CFTR Functions
    Symposium Presentation, Lyon (01/01/1900)
    Conferences Philippe Laudat
  • Ethnic distribution and phenotypic consequences of CF mutations
    Bethesda (01/01/1900)
    NIH Consensus Conference: Genetic Testing for Cystic Fibrosis
  • Molecular composition of GABAC receptors
    Symposium Presentation, Fort Lauderdale (01/01/1900)
    First Annual Conference in Association with Vision Research: Molecular, Cellular and Genetic Approaches to Function and Dysfunction of the Retina
  • “Molecular biology and rhinosinusitis” and “New directions in gene therapy for rhinology”
    Presentations, Philadelphia (01/01/1900)
    Cottle International Rhinology Centennial Conference
  • Functional analysis of ClC-2 chloride channels stably expressed in cystic fibrosis airway cells
    Symposium Presentation, Kansas City (01/01/1900)
    Annual Meeting Biophysical Society
  • Phenotypes Associated with Dysfunction of the Cystic Fibrosis Transmembrane Conductance Regulator
    Conference presentation, Lisbon (01/01/1900)
    Departamento de Genetica Humana Instituto Nacional de Saude

Recent News Articles and Media Coverage

Johns Hopkins Researchers Uncover Genes at Fault for Cystic Fibrosis-Related Intestinal Obstruction, Johns Hopkins Medicine (April 23, 2012)

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 

Comments

Loading...
Is this you? Edit Profile